Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 6.8% – Should You Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price fell 6.8% during mid-day trading on Tuesday . The company traded as low as $25.04 and last traded at $25.21. 156,085 shares changed hands during trading, a decline of 55% from the average session volume of 344,286 shares. The stock had previously closed at $27.04.

Analysts Set New Price Targets

A number of research analysts have commented on DNTH shares. TD Cowen initiated coverage on shares of Dianthus Therapeutics in a research report on Friday, December 20th. They issued a “buy” rating on the stock. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Oppenheimer lifted their price objective on Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research note on Monday, November 11th. Finally, Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Dianthus Therapeutics currently has an average rating of “Buy” and an average target price of $46.43.

Dianthus Therapeutics Trading Down 5.3 %

The firm has a market cap of $758.28 million, a PE ratio of -10.25 and a beta of 1.74. The firm has a 50 day moving average price of $24.70 and a 200-day moving average price of $26.60.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The firm had revenue of $2.17 million during the quarter, compared to analysts’ expectations of $1.07 million. Equities analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC boosted its stake in Dianthus Therapeutics by 40.5% in the third quarter. Janus Henderson Group PLC now owns 949,334 shares of the company’s stock valued at $25,936,000 after acquiring an additional 273,670 shares in the last quarter. State Street Corp boosted its position in shares of Dianthus Therapeutics by 101.4% in the 3rd quarter. State Street Corp now owns 821,131 shares of the company’s stock valued at $22,483,000 after purchasing an additional 413,425 shares during the period. Great Point Partners LLC grew its stake in Dianthus Therapeutics by 21.3% during the 2nd quarter. Great Point Partners LLC now owns 757,929 shares of the company’s stock worth $19,615,000 after buying an additional 132,929 shares during the last quarter. Braidwell LP grew its stake in Dianthus Therapeutics by 34.6% during the 3rd quarter. Braidwell LP now owns 493,687 shares of the company’s stock worth $13,517,000 after buying an additional 126,836 shares during the last quarter. Finally, Point72 Asset Management L.P. increased its position in Dianthus Therapeutics by 151.3% during the third quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company’s stock worth $11,984,000 after buying an additional 263,500 shares during the period. 47.53% of the stock is owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.